Latest news

• Lantus faces first biosimilar rival in Europe

  Meanwhile, Sanofi has not been resting on its laurels and has already filed for approval of a Lantus follow-up called Toujeo (formerly U300) which promises an improved pharmacodynamic profile with

• FDA to review Sanofi's Lantus successor

  The regulator will now spend the next few months assessing the safety and efficacy of Toujeo, formerly known as U300, which is a concentrated version of Lantus that has demonstrated an

• ADA: Novo says switching to Tresiba could reduce NHS costs

  formerly U300) is able to reduce rates of hypoglycaemia compared to Lantus as well as having less weight gain.

• Merck joins biosimilar Lantus race

  The French company is hoping to be able to bring its Lantus follow-up U300 - which promises to have less potential to cause hypoglycaemia than its parent product - before it loses

• Sanofi has been light on product launches, says CEO

  Sanofi is firmly focused on bringing a safer version of Lantus called U300 to market before it loses market exclusivity for its top-seller, and R&D chief Elias Zerhouni said